Journal article
Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naïve Crohn's Disease.
Abstract
BACKGROUND: There is a need to better understand the positioning of biologic therapies for long-term outcomes in biologic-naïve Crohn's disease (CD). We assessed the comparative effectiveness of infliximab and ustekinumab among induction responders for 1-year outcomes.
METHODS: This post hoc analysis included data from 220 biologic-naïve CD participants with response to induction therapy from 2 clinical trial programs. Participants achieving …
Authors
Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W; Narula N
Journal
Inflammatory Bowel Diseases, Vol. 29, No. 7, pp. 1015–1023
Publisher
Oxford University Press (OUP)
Publication Date
July 5, 2023
DOI
10.1093/ibd/izac168
ISSN
1078-0998